CN102215828A - 包含2-氧代-1-吡咯烷衍生物的延长释放制剂 - Google Patents

包含2-氧代-1-吡咯烷衍生物的延长释放制剂 Download PDF

Info

Publication number
CN102215828A
CN102215828A CN2009801455887A CN200980145588A CN102215828A CN 102215828 A CN102215828 A CN 102215828A CN 2009801455887 A CN2009801455887 A CN 2009801455887A CN 200980145588 A CN200980145588 A CN 200980145588A CN 102215828 A CN102215828 A CN 102215828A
Authority
CN
China
Prior art keywords
pharmaceutical composition
weight
release layer
alkyl
controlled release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801455887A
Other languages
English (en)
Chinese (zh)
Inventor
D·法纳拉
F·艾克曼
M·贝尔韦尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB SA filed Critical UCB SA
Publication of CN102215828A publication Critical patent/CN102215828A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN2009801455887A 2008-11-18 2009-11-17 包含2-氧代-1-吡咯烷衍生物的延长释放制剂 Pending CN102215828A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08105817 2008-11-18
EP08105817.4 2008-11-18
EP09100311 2009-06-02
EP09100311.1 2009-06-02
PCT/EP2009/065270 WO2010057869A1 (en) 2008-11-18 2009-11-17 Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410370727.9A Division CN104083341A (zh) 2008-11-18 2009-11-17 包含2-氧代-1-吡咯烷衍生物的延长释放制剂

Publications (1)

Publication Number Publication Date
CN102215828A true CN102215828A (zh) 2011-10-12

Family

ID=41395028

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2009801455887A Pending CN102215828A (zh) 2008-11-18 2009-11-17 包含2-氧代-1-吡咯烷衍生物的延长释放制剂
CN201410370727.9A Pending CN104083341A (zh) 2008-11-18 2009-11-17 包含2-氧代-1-吡咯烷衍生物的延长释放制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410370727.9A Pending CN104083341A (zh) 2008-11-18 2009-11-17 包含2-氧代-1-吡咯烷衍生物的延长释放制剂

Country Status (18)

Country Link
US (1) US8460712B2 (enExample)
EP (1) EP2358361B1 (enExample)
JP (2) JP5954889B2 (enExample)
KR (2) KR101788804B1 (enExample)
CN (2) CN102215828A (enExample)
AU (1) AU2009317279B2 (enExample)
BR (1) BRPI0921301A2 (enExample)
CA (1) CA2741038C (enExample)
DK (1) DK2358361T3 (enExample)
EA (1) EA019583B1 (enExample)
ES (1) ES2602606T3 (enExample)
HK (1) HK1198288A1 (enExample)
HU (1) HUE030963T2 (enExample)
IL (1) IL212271A (enExample)
MX (1) MX356281B (enExample)
PL (1) PL2358361T3 (enExample)
PT (1) PT2358361T (enExample)
WO (1) WO2010057869A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115721624A (zh) * 2021-08-25 2023-03-03 北京海美源医药科技有限公司 一种布立西坦药物组合物及其制备方法和其应用
CN117355296A (zh) * 2021-05-11 2024-01-05 阿德维斯尼公司 用于口服施用舒噻美的延长释放药物组合物

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101689688B1 (ko) * 2008-11-18 2016-12-26 유씨비 파마, 에스.에이. ２­옥소­１­피롤리딘 유도체를 포함하는 지연 방출형 제형
EP3397253A1 (en) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
US20190125725A1 (en) * 2016-05-12 2019-05-02 Jubilant Generics Limited Pharmaceutical compositions comprising brivaracetam
EP4337176B1 (en) * 2021-05-11 2025-07-16 Advicenne Prolonged-release pharmaceutical composition for oral administration of sultiame
TR2023017170A1 (tr) * 2023-12-13 2025-06-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Bri̇varasetam i̇çeren bi̇r saşe formülasyonu

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
AU2005325930B2 (en) 2005-01-27 2012-01-19 Alembic Limited Extended release formulation of Levetiracetam
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
WO2006088864A1 (en) * 2005-02-16 2006-08-24 Elan Pharma International Limited Controlled release compositions comprising levetiracetam
ES2403069T3 (es) * 2005-02-22 2013-05-13 Sun Pharma Advanced Research Company Ltd Composición oral de liberación controlada que contiene levetiracetam
CA2600282A1 (en) * 2005-03-29 2006-10-05 Roehm Gmbh Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
FR2897267A1 (fr) * 2006-02-16 2007-08-17 Flamel Technologies Sa Formes pharmaceutiques multimicroparticulaires pour administration per os
EP2041084B1 (en) * 2006-06-08 2013-11-06 UCB Pharma, S.A. Co-crystals of pyrrolidinones
NZ575171A (en) * 2006-08-31 2012-04-27 Aptalis Pharmatech Inc Drug delivery systems comprising solid solutions of weakly basic drugs
WO2008062446A2 (en) * 2006-09-14 2008-05-29 Alembic Limited An extended release composition of levetiracetam, which exhibits no adverse food effect
CN101801356B (zh) * 2007-09-21 2016-10-19 赢创罗姆有限公司 耐受乙醇影响的非阿片类的pH依赖性受控释放的药物组合物
DK2273975T3 (da) 2008-03-03 2014-06-30 Ucb Pharma Sa Farmaceutiske opløsninger, fremgangsmåde til fremstilling og terapeutiske anvendelser

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117355296A (zh) * 2021-05-11 2024-01-05 阿德维斯尼公司 用于口服施用舒噻美的延长释放药物组合物
CN115721624A (zh) * 2021-08-25 2023-03-03 北京海美源医药科技有限公司 一种布立西坦药物组合物及其制备方法和其应用

Also Published As

Publication number Publication date
ES2602606T3 (es) 2017-02-21
AU2009317279B2 (en) 2013-10-24
MX2011004572A (es) 2011-06-17
IL212271A0 (en) 2011-06-30
KR20110089184A (ko) 2011-08-04
JP5954889B2 (ja) 2016-07-20
EP2358361B1 (en) 2016-09-14
JP2015143256A (ja) 2015-08-06
WO2010057869A1 (en) 2010-05-27
CA2741038C (en) 2015-01-13
DK2358361T3 (en) 2016-12-12
EA019583B1 (ru) 2014-04-30
US20110274762A1 (en) 2011-11-10
CN104083341A (zh) 2014-10-08
PL2358361T3 (pl) 2017-02-28
CA2741038A1 (en) 2010-05-27
PT2358361T (pt) 2016-11-18
HK1198288A1 (en) 2015-03-27
KR101788804B1 (ko) 2017-10-20
IL212271A (en) 2016-10-31
JP2012509356A (ja) 2012-04-19
HUE030963T2 (en) 2017-06-28
EP2358361A1 (en) 2011-08-24
EA201100753A1 (ru) 2012-01-30
US8460712B2 (en) 2013-06-11
KR20170007528A (ko) 2017-01-18
BRPI0921301A2 (pt) 2015-12-29
MX356281B (es) 2018-05-22
AU2009317279A1 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
CN102215829B (zh) 含有2-氧代-1-吡咯烷衍生物的延长释放制剂
AU2010215646B2 (en) Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
HK1198288A1 (en) Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate
WO2008006528A2 (en) Pharmaceutical compositions comprising levetiracetam
WO2010103544A4 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
HK1159502A (en) Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate
HK1159503B (en) Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1159502

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20111012

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1159502

Country of ref document: HK